Main baseline characteristics of patients included in the study. by Jie Liu (15128)

Subjects:

(A) Monthly drug costs of patients in the ESAs group and Roxadustat group. by Jie Liu (15128)

Subjects:

PSM and Heckman regression results. by Qi Zhang (28502)

Subjects:

Study data. by Jie Liu (15128)

Subjects:

Regression results from a business risk perspective. by Qi Zhang (28502)

Subjects:

Mean hemoglobin levels of Roxadustat and ESAs groups over time. by Jie Liu (15128)

Subjects:

Fig 4 - by Maryann S. Watson (16879881)

Subjects:

Morisky score for ESAs group and Roxadustat group. by Jie Liu (15128)

Subjects:

Other robustness test regression results. by Qi Zhang (28502)

Subjects:

Species counts for all trap (kubben) catches across sites and seasons. by Maryann S. Watson (16879881)

Subjects:

Fig 5 - by Maryann S. Watson (16879881)

Subjects:

Association between current exposure to anti-rheumatic agents and ischemic stroke, with non-exposure and past exposure to each anti-rheumatic agent as reference. by Soo Min Ahn (10333246)

Subjects:

Species counts per catch for all fyke catches across sites and seasons. by Maryann S. Watson (16879881)

Subjects:

Baseline regression results. by Qi Zhang (28502)

Subjects:

Study population selection. by Soo Min Ahn (10333246)

Subjects:

Baseline characteristics of cases and controls. by Soo Min Ahn (10333246)

Subjects:

Risk of ischemic stroke according to the use of each anti-rheumatic agents. by Soo Min Ahn (10333246)

Subjects:

Univariate analysis results. by Qi Zhang (28502)

Subjects:

Patient flow diagram. by Jie Liu (15128)

Subjects:

Regression results for heterogeneity in corporate life cycle. by Qi Zhang (28502)

Subjects: